Date published: 2025-11-1

1-800-457-3801

SCBT Portrait Logo
Seach Input

FLJ36644 Inhibitors

FLJ36644 inhibitors refer to a class of chemical compounds that target the protein encoded by the *FLJ36644* gene, which is associated with various cellular pathways. These inhibitors function by interacting with the structure or active sites of the protein, thereby modulating its activity within the cell. *FLJ36644* is a gene of interest due to its role in regulating intracellular processes such as signal transduction, gene expression, or protein-protein interactions. By inhibiting the protein product of this gene, the associated compounds aim to disrupt its normal function, which could lead to altered cell behavior. The inhibitors often possess specific structural features that allow them to bind selectively to the target protein, preventing it from carrying out its typical biological functions.

The development and study of FLJ36644 inhibitors often focus on the specificity and potency of these compounds in modulating the targeted protein's function. Their design typically involves high-throughput screening or rational drug design approaches, with the goal of identifying molecules that can effectively bind to the protein of interest with minimal off-target effects. Chemical properties such as solubility, stability, and binding affinity are critical in determining the efficacy of FLJ36644 inhibitors. Understanding the structural and biochemical characteristics of these inhibitors helps to elucidate how they interact with the target protein and their potential impact on cellular processes. The inhibitors may also undergo structural modifications to enhance their binding efficiency and selectivity toward the *FLJ36644*-encoded protein.

Items 1 to 10 of 12 total

Display:

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

LY 294002

154447-36-6sc-201426
sc-201426A
5 mg
25 mg
$121.00
$392.00
148
(1)

Inhibits PI3K, potentially altering PI3K/Akt signaling pathways that FLJ36644 may be involved in.

PD 98059

167869-21-8sc-3532
sc-3532A
1 mg
5 mg
$39.00
$90.00
212
(2)

Inhibits MEK1/2, possibly affecting the MAPK/ERK pathway if FLJ36644 is associated with this pathway.

Rapamycin

53123-88-9sc-3504
sc-3504A
sc-3504B
1 mg
5 mg
25 mg
$62.00
$155.00
$320.00
233
(4)

Inhibits mTOR, which may disrupt signaling pathways involving FLJ36644 if it is part of the mTOR pathway.

SB 203580

152121-47-6sc-3533
sc-3533A
1 mg
5 mg
$88.00
$342.00
284
(5)

Inhibits p38 MAP kinase, potentially influencing the p38 MAPK stress response pathway linked with FLJ36644.

SP600125

129-56-6sc-200635
sc-200635A
10 mg
50 mg
$40.00
$150.00
257
(3)

Inhibits JNK, potentially affecting the JNK signaling pathway if FLJ36644 is a component of this pathway.

U-0126

109511-58-2sc-222395
sc-222395A
1 mg
5 mg
$63.00
$241.00
136
(2)

Inhibits MEK, potentially affecting the MAPK/ERK pathway and consequently FLJ36644 if it is involved in this pathway.

PP 2

172889-27-9sc-202769
sc-202769A
1 mg
5 mg
$92.00
$223.00
30
(1)

Inhibits Src-family tyrosine kinases, potentially modulating signaling cascades that include FLJ36644.

Dasatinib

302962-49-8sc-358114
sc-358114A
25 mg
1 g
$47.00
$145.00
51
(1)

Inhibits BCR-ABL and Src-family kinases, potentially altering pathways that involve FLJ36644.

Gefitinib

184475-35-2sc-202166
sc-202166A
sc-202166B
sc-202166C
100 mg
250 mg
1 g
5 g
$62.00
$112.00
$214.00
$342.00
74
(2)

Inhibits EGFR tyrosine kinase, potentially affecting signaling through pathways involving FLJ36644.

Bortezomib

179324-69-7sc-217785
sc-217785A
2.5 mg
25 mg
$132.00
$1064.00
115
(2)

Inhibits the proteasome, potentially disrupting protein degradation pathways involving FLJ36644.